Drug Profile
Eculizumab - Alexion AstraZencea Rare Disease
Alternative Names: 5G1-1; 5G1.1; Anti-C5 monoclonal antibody 5G1-1; h5G1.1; Monoclonal antibody 5G1-1; SolirisLatest Information Update: 08 Dec 2023
Price :
$50
*
At a glance
- Originator Alexion Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease; Alexion Pharmaceuticals; Brigham and Womens Hospital; Handok Inc
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemolytic uraemic syndrome; Myasthenia gravis; Neuromyelitis optica; Paroxysmal nocturnal haemoglobinuria
- Phase III Delayed graft function; Guillain-Barre syndrome
- Phase II Preeclampsia; Renal transplant rejection
- Clinical Phase Unknown COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
- No development reported Antiphospholipid syndrome; Heart transplant rejection
- Discontinued Adult respiratory distress syndrome; Age-related macular degeneration; Allergic asthma; Autoimmune haemolytic anaemia; Bullous pemphigoid; Dermatomyositis; Glomerulonephritis; Idiopathic thrombocytopenic purpura; Lupus nephritis; Membranous glomerulonephritis; Motor neuron disease; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 29 Nov 2023 Cedars-Sinai Medical Center in collaboration with Alexion Pharmaceuticals terminates a phase II trial in Preeclampsia (In adolescents, In the elderly, In adults) in USA (IV) due to PI moved institutions (NCT04725812)
- 06 Nov 2023 Alexion Pharmaceuticals completes phase III trial in Myasthenia gravis (In children, In adolescents, Treatment-experienced) in Japan, USA, Germany, Netherlands (IV) (NCT03759366) (EudraCT-2016-001384-37)
- 18 Oct 2023 Registered for Neuromyelitis optica (In adults) in China (IV)